From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
Ki-67 ↓ (N)
Ki-67 ↑ (N)
Total (N)
TK ↓ (n)
32
4a
36
TK ↑ (n)
2a
21
23
Total (n)
34
25
59